FDA’s Creation Of Pharmacologic Classes Is Mostly Reviewers’ Responsibility
This article was originally published in Pharmaceutical Approvals Monthly
A new chapter of CDER’s Manual of Policies and Procedures says reviewers should consider pharmacologic class in the IND stage as pharmacology information is submitted.
You may also be interested in...
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.